BME103 s2013:T900 Group6 L3: Difference between revisions
Line 30: | Line 30: | ||
| Sample Name || Ave. INTDEN* || Calculated μg/mL || Conclusion (pos/neg) | | Sample Name || Ave. INTDEN* || Calculated μg/mL || Conclusion (pos/neg) | ||
|- | |- | ||
| Positive Control || 7301649|| | | Positive Control || 7301649|| 62.48 || N/A | ||
|- | |- | ||
| Negative Control || 3786507.33|| | | Negative Control || 3786507.33|| 29.57|| N/A | ||
|- | |- | ||
| Tube Label: 1-1 Patient ID: ____ rep 1 || 7457625.66 || | | Tube Label: 1-1 Patient ID: ____ rep 1 || 7457625.66 || 63.94 || pos | ||
|- | |- | ||
| Tube Label: 1-2 Patient ID: ____ rep 2 || 9087739.66 || | | Tube Label: 1-2 Patient ID: ____ rep 2 || 9087739.66 || 79.2 || pos | ||
|- | |- | ||
| Tube Label: 1-3Patient ID: ____ rep 3 || 4817516.33 || | | Tube Label: 1-3Patient ID: ____ rep 3 || 4817516.33 || 39.23 || neg | ||
|- | |- | ||
| Tube Label:___ Patient ID: ____ rep 1 || 3558606.33 || | | Tube Label:___ Patient ID: ____ rep 1 || 3558606.33 || 27.44 || neg | ||
|- | |- | ||
| Tube Label:___ Patient ID: ____ rep 2 || 4247969.66 || | | Tube Label:___ Patient ID: ____ rep 2 || 4247969.66 || 33.89 || neg | ||
|- | |- | ||
| Tube Label:___ Patient ID: ____ rep 3 || 4704281 || | | Tube Label:___ Patient ID: ____ rep 3 || 4704281 || 38.17 || neg | ||
|} | |} | ||
<nowiki>* Ave. INTDEN = Average of ImageJ integrated density values from three Fluorimeter images</nowiki> | <nowiki>* Ave. INTDEN = Average of ImageJ integrated density values from three Fluorimeter images</nowiki> |
Revision as of 18:41, 15 April 2013
BME 103 Spring 2013 | Home People Lab Write-Up 1 Lab Write-Up 2 Lab Write-Up 3 Course Logistics For Instructors Photos Wiki Editing Help | |||||||||||||||||||||||||||||||||||||||||
OUR TEAMLAB 3 WRITE-UPOriginal System: PCR ResultsPCR Test Results
* Ave. INTDEN = Average of ImageJ integrated density values from three Fluorimeter images
Bayes Theorem equation: P(A|B) = P(B|A) * P(A) / P(B)
Calculation 3: The probability that the patient will develop cancer, given a cancer DNA sequence.
New System: Design StrategyWe concluded that a good system Must Have:
New System: Machine/ Device EngineeringSYSTEM DESIGN
KEY FEATURES We chose to include these new features
[OR] We chose keep the devices the same as the original system
INSTRUCTIONS
New System: ProtocolsDESIGN We chose to include these new approaches/ features
[OR] We chose keep the protocols the same as the original system
PROTOCOLS
New System: Research and DevelopmentBACKGROUND
DESIGN
New System: Software[THIS SECTION IS OPTIONAL. If your team has creative ideas for new software, and new software is a key component included in your new protocols, R&D, or machine design, you may describe it here. You will not receive bonus points, but a solid effort may raise your overall page layout points. If you decide not to propose new software, please delete this entire section, including the ==New System: Software== header.]
|